Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues.

@article{Dusheiko2013TreatmentOH,
  title={Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues.},
  author={Geoffrey Dusheiko},
  journal={Liver international : official journal of the International Association for the Study of the Liver},
  year={2013},
  volume={33 Suppl 1},
  pages={
          137-50
        }
}
Interferon alpha has restricted efficacy in as much as only a proportion of patients show a response. However, in appropriately selected HBeAg-positive and HBeAg-negative patients, sustained suppression of viral replication can be achieved, and HBeAg or even HBsAg seroconversion can be attained. Thus, finite course of interferon alpha can be successful, and offer an advantage to patient. Interferon (IFN) remains a benchmark therapy for chronic hepatitis B. The main advantages of IFN-α over… CONTINUE READING
Highly Cited
This paper has 40 citations. REVIEW CITATIONS
Tweets
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 18 citations